Older adults discharged from hospitals with sedative prescriptions they had never taken before faced elevated rates of falls, emergency department visits, and death within 30 days, according to two primary studies published in 2025. A population-based cohort study covering nearly 1.9 million Ontario patients aged 66 and older found that 13.2 percent filled a sedative prescription within seven days of leaving the hospital, and 31.0 percent of those patients had no prior history of using such drugs. The findings sharpen a question hospitals have largely left unanswered: whether targeted pharmacy interventions right after discharge could prevent injuries among the most vulnerable subset of patients, those encountering sedatives for the first time.
Post-discharge sedatives and the 30-day risk window
The Ontario cohort study, published in the Canadian Medical Association Journal, tracked 1,868,484 older adults discharged alive between 2003 and 2023. Researchers used linked pharmacy claims and hospital records to identify who filled prescriptions for benzodiazepines, Z-drugs, and other sedatives shortly after going home. Among the 13.2 percent who filled any sedative within seven days, the 30-day fall rate reached 1.6 percent and the 30-day emergency department visit rate hit 21.3 percent. Those numbers carry extra weight because nearly a third of the sedative users, 31.0 percent, were sedative-naive before admission, meaning the drugs were started during or immediately after their hospital stay rather than continued from a long-standing prescription.
That distinction matters for clinical decision-making. Patients already accustomed to sedatives carry their own risks, but their bodies have at least partially adapted to side effects such as drowsiness and impaired balance. A patient who has never taken a sedative and then fills a new prescription days after discharge faces a steeper pharmacological adjustment at the exact moment they are also recovering from an acute illness, navigating a changed home environment, and often managing multiple new medications at once.
The 30-day window after discharge is already recognized as a high-risk period for readmissions and medication errors. Adding a new sedative during this interval may compound existing vulnerabilities: orthostatic hypotension from antihypertensives, lingering weakness from hospitalization, and unfamiliar surroundings if the patient has moved to a rehabilitation facility or family member’s home. The Ontario data suggest that even a relatively modest absolute fall rate translates into a substantial number of serious injuries when applied across nearly two million discharges.
Trial data linking sedative patterns to adverse drug events
A separate line of evidence reinforces the population-level findings. A secondary analysis of a deprescribing trial examined sedative prescribing patterns among hospitalized older adults and sorted patients by whether their sedatives were continued at discharge, newly started, or deprescribed. The analysis tied continued or new sedative use at discharge to higher rates of adverse drug events and falls within 30 days, while patients whose sedatives were stopped before they left the hospital fared better.
The MedSafer data add a practical dimension the Ontario cohort alone cannot supply. Because the parent trial was designed as a structured deprescribing intervention, its secondary analysis offers a window into what happens when clinicians actively decide to stop a sedative before discharge versus letting the prescription carry forward by default. The contrast suggests that the act of deprescribing itself, rather than simply identifying at-risk patients, may reduce harm. Hospitals that treat discharge medication lists as a passive continuation of inpatient orders could be missing a concrete opportunity to cut fall rates.
Taken together, the observational Ontario cohort and the randomized-trial context of MedSafer converge on a similar message: new or continued sedatives at discharge are not benign. While causality cannot be definitively assigned from these analyses alone, the consistency of associations across different designs strengthens the case that sedative decisions at the transition from hospital to home matter for short-term safety.
Why a pharmacist review for sedative-naive patients could change outcomes
Both studies point toward a testable intervention: a structured pharmacist review within 48 hours of discharge, focused specifically on patients who were sedative-naive before admission. The logic is straightforward. General post-discharge medication reconciliation programs already exist at many hospitals, but they spread pharmacist time across all discharged patients regardless of risk profile. A review targeted at the 31.0 percent of sedative users who had no prior exposure would concentrate resources on the group most likely to experience a first adverse reaction.
In practice, such a review could include confirming the indication for the sedative, checking for drug–drug interactions, counseling patients and caregivers about fall precautions, and, when appropriate, recommending dose reductions or tapering plans to the prescribing clinician. Pharmacists could also flag patients whose home environments pose particular risks, such as cluttered hallways or lack of nighttime lighting, and coordinate with nursing or social work teams for home safety assessments.
The hypothesis carries limits. Neither the Ontario cohort nor the MedSafer analysis directly tested a pharmacist-led intervention against a control group receiving broader reviews. The Ontario data, drawn from administrative health databases, do not include patient-level dosing details, clinical indications for the sedative, or how long the prescription was intended to last. Without that granularity, it is difficult to separate patients who received a short course for acute insomnia from those placed on open-ended prescriptions. The MedSafer secondary analysis, for its part, does not report direct 30-day mortality counts or cause-of-death linkage, which limits the strength of any mortality claim.
Hospital-level variation also remains unmeasured. Neither study reports whether certain institutions already run deprescribing protocols, how discharge workflows differ across sites, or what clinician rationale drives the decision to send a patient home with a new sedative. Those gaps mean the size of the potential benefit from a targeted pharmacist review is still an open question, even if the direction of effect is consistent across both datasets.
Unanswered questions and what older patients should watch for
Several pieces of the puzzle are still missing. The Ontario study spans two decades of discharges, a period during which prescribing norms, formulary restrictions, and geriatric care standards all shifted. Whether the risk profile observed across that full window applies equally to patients discharged in recent years is not yet clear. The MedSafer analysis draws on a trial population that may differ from typical community hospitals in terms of patient complexity, staffing, and access to pharmacists trained in deprescribing, which could limit generalizability.
Important clinical nuances also remain underexplored. For example, it is unclear whether certain sedatives, such as short-acting benzodiazepines, carry lower post-discharge risk than longer-acting agents, or whether nighttime-only dosing meaningfully reduces daytime falls. Similarly, the studies do not fully address how cognitive impairment, delirium during hospitalization, or pre-existing gait instability modify sedative-related risks once patients return home.
For older adults and caregivers, the immediate lesson is practical rather than statistical. Any new sedative prescribed around the time of a hospital stay should trigger questions: Why is this medication needed? How long should it be taken? What signs of trouble-such as new confusion, unsteadiness, or near-falls-should prompt a call to the clinician or a return to the emergency department? Bringing a written list of all medications, including over-the-counter sleep aids and herbal products, to follow-up visits can help clinicians spot risky combinations.
Clinicians, meanwhile, may find value in treating sedative-naive status as a simple, actionable risk marker. Flagging these patients in electronic health records, prioritizing them for early post-discharge phone calls, or embedding pharmacist consults into discharge pathways are all feasible steps that do not require new drugs or complex technology. Future research will need to test whether such targeted strategies measurably reduce falls, emergency visits, and deaths within the 30-day window that both major studies have identified as a period of heightened vulnerability.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
